Publications by authors named "Wai Yi Man"
Article Synopsis
- Lung cancer remains the leading cause of cancer death globally, prompting a need to evaluate its trends in the UK, especially after significant declines in smoking.
- This study utilized UK primary care databases to analyze lung cancer incidence rates, prevalence, and survival rates from 2000 to 2021, involving over 11 million participants and more than 45,500 lung cancer cases.
- Findings revealed an overall increase in lung cancer incidence, particularly among females over 50, with median survival rates improving from 6.6 months (2000-2004) to 10 months (2015-2019), and younger patients generally faring better than older ones.
Article Synopsis
- The study aimed to evaluate the impact of the UK MHRA's March 2019 Risk Minimisation Measures (RMM) on the usage of fluoroquinolones using interrupted time series (ITS) methods.
- It analyzed monthly and quarterly fluoroquinolone usage data from various healthcare settings between 2012 and 2022, employing segmented regression and ARIMA models to assess changes across different age groups.
- Results showed significant reductions in fluoroquinolone usage after the RMM implementation across multiple databases, but some statistical issues such as heteroscedasticity and non-normality were observed in hospital-level data.
Article Synopsis
- - The study analyzed the incidence and survival rates of prostate cancer in the UK from 2000 to 2021 using data from two primary care databases, CPRD GOLD and Aurum, involving over 198,000 patients aged 18 and older.
- - It found that the incidence of prostate cancer rose significantly during the study period, from 109 to 159 cases per 100,000 person-years, with the highest rates observed in men aged 80 to 89.
- - Survival rates at 1, 5, and 10 years post-diagnosis were found to be stable, around 93% for 1 year, 72% for 5 years, and 53% for 10 years,
Article Synopsis
- Breast cancer is the most common cancer diagnosed in females worldwide, but there is limited information regarding trends in males, prompting a study of breast cancer in the UK from 2000 to 2021 for both sexes.
- The study analyzed over 5.8 million females and 5.5 million males, finding crude incidence rates of 194.4 per 100,000 for females and just 1.16 for males, with both genders experiencing a roughly 2.5-fold increase in prevalence over time.
- Survival rates after diagnosis were relatively high for both sexes, with females showing improvement over time, especially those aged 50-70, while males exhibited no clear trends, and changes in female incidence were linked to
Article Synopsis
- This study investigates treatment patterns for Systemic Lupus Erythematosus (SLE) in both adults and children, highlighting the lack of real-world data on medication use, particularly in childhood-onset SLE (cSLE).
- Researchers analyzed data from over 11,000 SLE patients across multiple European countries, finding that the majority were female, with specific first-line treatments being hydroxychloroquine and glucocorticoids for both demographics.
- The findings indicate that while adult treatment aligns with guidelines, the high use of glucocorticoids in children suggests a need for alternatives and specialized treatment recommendations for pediatric patients.
Article Synopsis
- The study investigates how the COVID-19 pandemic affected the survival rates of common solid tumors in the UK healthcare system, particularly focusing on cancers like breast, colorectal, lung, and pancreatic.
- Researchers analyzed data from over 12 million patients from 2000 to 2022, revealing a decrease in cancer diagnoses in 2020 followed by some recovery in 2021-2022, while short-term survival rates slightly declined for those diagnosed during the pandemic.
- Findings indicate that while survival rates were mostly stable before the pandemic, they declined marginally post-2020, especially for colorectal cancer, emphasizing the urgent need for the UK National Health Service to improve cancer screening and treatment to reduce the backlog caused by the pandemic.
Background: The COVID-19 pandemic affected cancer screening, diagnosis and treatments. Many surgeries were substituted with bridging therapies during the initial lockdown, yet consideration of treatment side effects and their management was not a priority.
Objectives: To examine how the changing social restrictions imposed by the pandemic affected incidence and trends of endocrine treatment prescriptions in newly diagnosed (incident) breast and prostate cancer patients and, secondarily, endocrine treatment-related outcomes (including bisphosphonate prescriptions, osteopenia and osteoporosis), in UK clinical practice from March 2020 to June 2022.
The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study.
Front Oncol
March 2024
Introduction: The COVID-19 pandemic had collateral effects on many health systems. Cancer screening and diagnostic tests were postponed, resulting in delays in diagnosis and treatment. This study assessed the impact of the pandemic on screening, diagnostics and incidence of breast, colorectal, lung, and prostate cancer; and whether rates returned to pre-pandemic levels by December, 2021.
View Article and Find Full Text PDFObjective: To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications.
Methods: We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods.
Background: Although vaccines have proved effective to prevent severe COVID-19, their effect on preventing long-term symptoms is not yet fully understood. We aimed to evaluate the overall effect of vaccination to prevent long COVID symptoms and assess comparative effectiveness of the most used vaccines (ChAdOx1 and BNT162b2).
Methods: We conducted a staggered cohort study using primary care records from the UK (Clinical Practice Research Datalink [CPRD] GOLD and AURUM), Catalonia, Spain (Information System for Research in Primary Care [SIDIAP]), and national health insurance claims from Estonia (CORIVA database).